TrialAnnals of hematology2021

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.

Michael Heuser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.